Alginate encapsulated human mesenchymal stem cells suppress syngeneic glioma growth in the immunocompetent rat

Journal of Microencapsulation

Volumn 28, Issue 7, 2011, Pages 621-627

  Kleinschmidt, Kerstin ^a   Klinge, Petra M ^b   Stopa, Edward ^c   Wallrapp, Christine ^d   Glage, Silke ^e   Geigle, Peter ^d   Brinker, Thomas ^a,b  

^a INTERNATIONAL NEUROSCIENCE INSTITUTE   (Germany)

^b BROWN UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

^d CellMed AG   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cell therapy; Endostatin; Glioma; Mesenchymal cells

Indexed keywords

ALGINIC ACID; ENDOSTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL FREE SYSTEM; CELL THERAPY; CELL TRANSPLANTATION; CONTROLLED STUDY; FEMALE; GLIOMA CELL; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; NANOENCAPSULATION; NONHUMAN; RAT; TUMOR VASCULARIZATION; TUMOR VOLUME;

ALGINATES; ANGIOGENESIS INHIBITORS; ANIMALS; CAPSULES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COATED MATERIALS, BIOCOMPATIBLE; ENDOSTATINS; FEMALE; GLIOMA; HUMANS; IMMUNITY, CELLULAR; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; RATS; TIME FACTORS; TISSUE THERAPY;

EID: 80053397804     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2011.599441     Document Type: Article

References (29)

1. Albesiano E, Han JE, Lim M. Mechanisms of local immunoresistance in glioma. Neurosurg Clin N Am, 2010;21:17-29.
2. Bjerkvig R, Read TA, Vajkoczy P, Aebischer P, Pralong W, Platt S, Melvik JE, Hagen A, Dornish M. Cell therapy using encapsulated cells producing endostatin. Acta Neurochir Suppl, 2003;88:137-41.
3. Borlongan CV. Cell therapy for stroke: Remaining issues to address before embarking on clinical trials. Stroke, 2009;40:S146-8.
4. Druckrey H, Schagen B, Ivankovic S. [Induction of neurogenic malignancies by one single dose of ethyl-nitrosourea (ENU) given to newborn and juvenile BD IX-strain rats] Erzeugung neurogener Malignome durch einmalige Gabe von Athyl-nitrosoharnstoff (ANH) an neugeborene und junge BD IX-Ratten. Z Krebsforsch, 1970;74:141-61.
5. Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S, Yoon SS. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res, 2008;14:1529-39. (Pubitemid 351413938)
6. Goren A, Dahan N, Goren E, Baruch L, Machluf M. Encapsulated human mesenchymal stem cells: A unique hypoimmunogenic platform for longterm cellular therapy. FASEBJ, 2010;24:22-31.
7. Heile AM, Wallrapp C, Klinge PM, Samii A, Kassem M, Silverberg G, Brinker T. Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury. Neurosci Lett, 2009;463:176-81.
8. Huang G, Chen L. Discrepancies between antiangiogenic and antitumor effects of recombinant human endostatin. Cancer Biother Radiopharm, 2009;24:589-96.
9. Joki T, Machluf M, Atala A, Zhu J, Seyfried NT, Dunn IF, Abe T, Carroll RS, Black PM. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol, 2001;19:35-9. (Pubitemid 32051953)
10. Klinge PM, Harmening K, Miller MC, Heile A, Wallrapp C, Geigle P, Brinker T. Encapsulated native and Glucagon-like peptide-1 transfected human mesenchymal stem cells in a transgenic mice model of Alzheimer's disease. Neurosci Lett, 2011;497(1):6-10.
11. Kucerova L, Matuskova M, Hlubinova K, Altanerova V, Altaner C. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer, 2010;9:129.
12. Lindvall O, Wahlberg LU. Encapsulated cell biodelivery of GDNF: A novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease? Exp Neurol, 2008;209:82-8.
13. Momin EN, Vela G, Zaidi HA. Quinones-Hinojosa A. The oncogenic potential of mesenchymal stem cells in the treatment of cancer: Directions for future research. Curr Immunol Rev, 2010;6:137-48.
14. Motaln H, Schichor C, Lah TT. Human mesenchymal stem cells and their use in cell-based therapies. Cancer, 2010;116:2519-30.
15. Murua A, Portero A, Orive G, Hernandez RM, de Castro M, Pedraz JL. Cell microencapsulation technology: Towards clinical application. J Control Release, 2008;132:76-83.
16. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res, 2005;65:3307-18. (Pubitemid 40524615)
17. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, Bizen A, Honmou O, Niitsu Y, Hamada H. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther, 2004;11:1155-64. (Pubitemid 39117311)
18. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell, 1997;88:277-85. (Pubitemid 28015876)
19. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell, 2009;15:220-31.
20. Pradilla G, Legnani FG, Petrangolini G, Francescato P, Chillemi F, Tyler BM, Gaini SM, Brem H, Olivi A, DiMeco F. Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas. Neurosurgery, 2005;57:1032-40. (Pubitemid 41579739)
21. Read TA, Sorensen DR, Mahesparan R, Enger PO, Timpl R, Olsen BR, Hjelstuen MH, Haraldseth O, Bjerkvig R. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol, 2001;19:29-34. (Pubitemid 32054367)
22. Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI, Jensen T G, Kassem M. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol, 2002;20:592-6. (Pubitemid 34595153)
23. Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, Pastorino S, Yang M, Hoffman RM, Kesari S, et al. From the cover: Feature article: Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci USA, 2011;108:4274-80.
24. Stagg J. Mesenchymal stem cells in cancer. Stem Cell Rev, 2008;4:119-24.
25. Sughrue ME, Yang I, Kane AJ, Rutkowski MJ, Fang S, James CD, Parsa AT. Immunological considerations of modern animal models of malignant primary brain tumors. J Transl Med, 2009;7:84.
26. Weiner NE, Pyles RB, Chalk CL, Balko MG, Miller MA, Dyer CA, Warnick RE, Parysek LM. A syngeneic mouse glioma model for study of glioblastoma therapy. J Neuropathol Exp Neurol, 1999;58:54-60. (Pubitemid 29053026)
27. Yang SY, Liu H, Zhang JN. Gene therapy of rat malignant gliomas using neural stem cells expressing IL-12. DNA Cell Biol, 2004;23:381-9. (Pubitemid 38850385)
28. Yu JM, Jun ES, Bae YC, Jung JS. Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev, 2008;17:463-73. (Pubitemid 351948199)
29. Zimmermann U, Thurmer F, Jork A, Weber M, Mimietz S, Hillgartner M, Brunnenmeier F, Zimmermann H, Westphal I, Fuhr G, et al. A novel class of amitogenic alginate microcapsules for long-term immunoisolated transplantation. Ann NY Acad Sci, 2001;944:199-215. (Pubitemid 34053307)